These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 33837554)

  • 41. Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance.
    Alloush R; van Lint J; van Marum RJ; Hermens WWAJJ; Jessurun NT
    Expert Opin Drug Saf; 2024 Jul; 23(7):925-935. PubMed ID: 37961907
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adverse Drug Reactions to Opioids: A Study in a National Pharmacovigilance Database.
    Gustafsson M; Matos C; Joaquim J; Scholl J; van Hunsel F
    Drug Saf; 2023 Nov; 46(11):1133-1148. PubMed ID: 37824028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The drugs that mostly frequently induce gynecomastia: A national case - noncase study.
    Batteux B; Llopis B; Muller C; Khouri C; Moragny J; Liabeuf S; Masmoudi K; Gras V;
    Therapie; 2020; 75(3):225-238. PubMed ID: 31471065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
    Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
    de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
    Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hospital databases for the identification of adverse drug reactions: A 2-year multicentre study in 9 French general hospitals.
    Osmont MN; Degremont A; Jantzem H; Audouard-Marzin Y; Lalanne S; Carlhant-Kowalski D; Bellissant E; Oger E; Polard E
    Br J Clin Pharmacol; 2021 Feb; 87(2):471-482. PubMed ID: 32484575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends in adverse drug reactions related to oral weak opioid analgesics in therapeutic use in adults: A 10-year French vigilances retrospective study.
    Caré W; Pinel S; Dufayet L; Langrand J; Micallef J; Vodovar D
    Fundam Clin Pharmacol; 2023 Dec; 37(6):1205-1217. PubMed ID: 37400273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
    Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
    Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does spontaneous adverse drug reactions' reporting differ between different reporters? A study in Toulouse Pharmacovigilance Centre.
    Nicol C; Moulis F; Bondon-Guitton E; Durrieu G; Montastruc JL; Bagheri H
    Therapie; 2019 Oct; 74(5):521-525. PubMed ID: 31029402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.
    Taugourdeau-Raymond S; Rouby F; Default A; Jean-Pastor MJ;
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1103-7. PubMed ID: 22349162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
    Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
    Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France.
    Montastruc JL; Lapeyre-Mestre M; Bagheri H; Fooladi A
    Fundam Clin Pharmacol; 2002 Oct; 16(5):343-6. PubMed ID: 12608357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
    Aagaard L; Hansen EH
    Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance.
    Fornasier G; Taborelli M; Francescon S; Polesel J; Aliberti M; De Paoli P; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):795-802. PubMed ID: 29785683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Global Versus Indian Perspective of Pioglitazone-induced Adverse Drug Reactions Including Bladder Cancer: A Comparative Retrospective Pharmacovigilance Analysis.
    Bhushan S; Ray RS; Prakash J; Singh GN
    Clin Ther; 2019 Nov; 41(11):2252-2262. PubMed ID: 31543285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis.
    Kunac DL; Tatley MV
    Drug Saf; 2011 Jan; 34(1):59-71. PubMed ID: 21142271
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychiatric adverse drug reactions in the paediatric population.
    Ekhart C; Vries T; Hunsel FV
    Arch Dis Child; 2020 Aug; 105(8):749-755. PubMed ID: 32060030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study.
    Leone R; Moretti U; D'Incau P; Conforti A; Magro L; Lora R; Velo G
    Drug Saf; 2013 Apr; 36(4):267-76. PubMed ID: 23475583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.